Anticancer activity of hydroxy- and sulfonamide-azobenzene platinum(II) complexes in cisplatin-resistant ovarian cancer cells

Katia G. Samper, Sierra C. Marker, Pau Bayón, Samantha N. MacMillan, Ivan Keresztes, Òscar Palacios, Justin J. Wilson

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

© 2017 Elsevier Inc. The syntheses of three platinum(II) complexes bearing sulfonamide- ( (E)-2-(4-methylphenylsulfonamido)-2′,6′-difluoroazobenzene, HL1) and hydroxy-azo-2,6-difluorobenzene ((E)-2-((2,6-difluorophenyl)diazenyl)phenol, HL2) bidentate ligands is described. These complexes, [Pt(L1)(DMSO)Cl] (1), [Pt(L2)(DMSO)Cl] (2), and [Pt(L2)2] (3), were characterized by multinuclear NMR spectroscopy, mass spectrometry, and X-ray crystallography. Despite bearing azobenzene functional groups, none of the three complexes undergo photoisomerization. The anticancer activities of these complexes were evaluated in wild-type (A2780) and cisplatin-resistant (A2780CP70) ovarian cancer cells. All three complexes exhibited IC50 values below 10 μM and displayed similar activity in both A2780 and A2780CP70 cell lines, indicating that they are not cross-resistant with cisplatin. The DNA-binding properties of 1–3 were investigated by circular dichroism spectroscopy and by agarose gel electrophoresis. Both studies suggest that 1 and 2 form monofunctional DNA adducts.
Original languageEnglish
Pages (from-to)102-110
JournalJournal of Inorganic Biochemistry
Volume174
DOIs
Publication statusPublished - 1 Sep 2017

Keywords

  • Antitumor drug
  • Azobenzene
  • Cisplatin
  • Cisplatin resistance
  • Ovarian cancer
  • Photodynamic therapy

Fingerprint Dive into the research topics of 'Anticancer activity of hydroxy- and sulfonamide-azobenzene platinum(II) complexes in cisplatin-resistant ovarian cancer cells'. Together they form a unique fingerprint.

Cite this